From: The impact of incorporating Bayesian network meta-analysis in cost-effectiveness analysis - a case study of pharmacotherapies for moderate to severe COPD
Intervention
Rate ratios (95% CrI)
PMA
NMA
Placebo
ICS
0.81 (0.68-0.95)
0.81 (0.72-0.91)
LABA
0.87 (0.75-1.01)
0.87 (0.78-0.96)
ICS + LABA
0.71 (0.60-0.88)
0.70 (0.62-0.79)
LAMA
0.73 (0.59-0.91)
0.74 (0.67-0.82)